Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database

• Published in: Scientific reports Vol. 15; no. 1; pp. 6838 - 14
• Main Authors: He, Mengjiao, Yang, Jiale, Yan, Simin, Shu, Qing, Liu, Peng Cheng
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.02.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4023; 692/4023/1670/1613; Adalimumab - adverse effects; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antibodies, Monoclonal - adverse effects; Bayesian analysis; Certolizumab Pegol - adverse effects; Child; Child, Preschool; Databases, Factual; Disproportionality analysis; Etanercept; Etanercept - adverse effects; FAERS database; Female; Humanities and Social Sciences; Humans; Infant; Infliximab; Infliximab - adverse effects; Inhibitors; Lupus; Lupus Erythematosus, Systemic - chemically induced; Lupus Erythematosus, Systemic - epidemiology; Lupus nephritis; Male; Middle Aged; Monoclonal antibodies; multidisciplinary; Neural networks; Pericarditis; Pharmacovigilance; Pleurisy; Science; Science (multidisciplinary); Statistical analysis; Systemic lupus erythematosus; Tumor Necrosis Factor Inhibitors - adverse effects; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Young Adult; Systemic lupus erythematosus; FAERS database; Pharmacovigilance; Disproportionality analysis

This study characterized the risk and characteristics of tumor necrosis factor-α (TNF-α) inhibitors-induced systemic lupus erythematosus (SLE) in a mass medication population based on the FAERS database. Using the Standardized MedDRA Query (SMQ), adverse drug reaction (ADR) reports related to SLE of...